Noa Therapeutics

Profile

Noa Therapeutics has developed a proprietary NRF2-biased platform approach to AhR, a validated yet historically sub-optimally drugged master regulator of innate immunity and barrier homeostasis. Selectively biasing AhR recruitment away from sub-optimal canonical CYP1A1 pathways, through discrete coregulator engagement and co-recruitment of NRF2 to HMOX1, Noa has demonstrated safe AhR agonism and a selective transcriptional response toward a durable, non-immunosuppressive, inflammation resolution.

Noa Therapeutics Logo

Website

noatherapeutics.com

Contact


Event details

Date: January 12 - 14, 2026

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total